查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1242138

细胞存活率化验的全球市场

Cell Viability Assays
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

细胞存活率化验的全球市场在2030年前将达到75亿美元

在COVID-19后改变的商务环境中，2022年43亿美元的细胞存活率化验的全球市场，2030年之前将达到75亿美元的规模，在2022年～2030年预计将以年复合成长率7.1％增长。本报告所分析之市场区隔之一的消耗品，年复合成长率将记录7.8％，到分析期间结束时将达到48亿美元。考虑疫情后的復苏，仪器领域今后8年的年复合成长率将修正为6％。

美国市场估算为13亿美元，中国则将以年复合成长率6.6％的速度成长。

美国的细胞存活率化验市场在2022年估算为达到13亿美元。作为世界第2大经济大国的中国，在2022年～2030年预计将以年复合成长率6.6％推移，在2030年前将达到13亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以6.7％和5.7％的速度成长。在欧洲市场中，德国以年复合成长率5.7％成长。

调查对像企业范例

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioTek 仪器s, Inc.
  • Biotium, Inc.
  • Creative Bioarray
  • Danaher Corporation
  • GE Healthcare
  • Merck KgaA
  • PerkinElmer, Inc.
  • Promega Corporation
  • Thermo Fisher Scientific, Inc.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP10953

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Cell Viability Assays Market to Reach $7.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Cell Viability Assays estimated at US$4.3 Billion in the year 2022, is projected to reach a revised size of US$7.5 Billion by 2030, growing at aCAGR of 7.1% over the period 2022-2030. Consumables, one of the segments analyzed in the report, is projected to record 7.8% CAGR and reach US$4.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 6.6% CAGR

The Cell Viability Assays market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Select Competitors (Total 11 Featured) -

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioTek Instruments, Inc.
  • Biotium, Inc.
  • Creative Bioarray
  • Danaher Corporation
  • GE Healthcare
  • Merck KgaA
  • PerkinElmer, Inc.
  • Promega Corporation
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Cell Viability Assays - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Cell Viability Assays Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell Viability Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell Viability Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cell Viability Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • JAPAN
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • CHINA
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: China 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: China 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • EUROPE
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cell Viability Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Cell Viability Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Cell Viability Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • FRANCE
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: France 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: France 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • GERMANY
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2023 & 2030

IV. COMPETITION